Stockscreener 앱 받기
45.94
2.81%
-1.33
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
Is Praxis Precision Medicines Inc. stock reversal real or fakeSecure Trading Strategy Based on Technical Analysis - Newser
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaReal Market Tracker with Price Action Tools - Newser
Will Praxis Precision Medicines Inc. bounce back from current supportFree Capital Efficiency Optimized Stock Alerts - Newser
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
Reversal indicators forming on Praxis Precision Medicines Inc. stockFree Weekly Potential Breakout Stock List - Newser
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - WV News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines: A Dual-Platform Innovator Capturing the Future of Precision Neurology - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside C - GuruFocus
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewswire
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data - Investing.com India
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $33 to $155 - 富途牛牛
Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024) - Yahoo Finance
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Reports Promising Study Results - TipRanks
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines to Participate in Virtual Fireside Chat Hosted by Truist Securities - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News - GuruFocus
Praxis Precision Medicines Shares Surge on Promising Epilepsy Drug Data - MSN
Guggenheim raises Praxis Precision Medicines stock price target on positive seizure drug data - Investing.com Australia
Praxis Precision Medicines stock holds Buy rating at TD Cowen on promising seizure data - Investing.com Canada
Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts - Seeking Alpha
Praxis Precision Medicines stock price target raised by Wedbush to $33 - Investing.com
Praxis’ epilepsy drug cut seizure frequency in mid-stage trial - Endpoints News
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures - Yahoo Finance
Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao - TipRanks
Praxis Precision Medicines, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:PRAX) - Seeking Alpha
A brain biotech slumps even with ‘best case’ seizure data - BioPharma Dive
Quitter jitters? Dropouts mar Praxis FOS vormatrigine phase II - BioWorld MedTech
Praxis Precision Medicines Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Praxis (PRAX) Q2 Loss Widens 90% - The Motley Fool
Praxis Announces Positive Results from RADIANT Study - TipRanks
Praxis Precision Q3 2025 slides: RADIANT study reveals promising epilepsy results - Investing.com Nigeria
Praxis Precision Medicines and the Breakthrough Potential of Vormatrigine in Focal Epilepsy - AInvest
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Praxis Precision stock jumps on trial data (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines stock soars after positive epilepsy drug results By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock soars after positive epilepsy drug results - Investing.com
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine - GlobeNewswire
Breakthrough Epilepsy Treatment Achieves 56% Seizure Reduction, Complete Freedom for 22% of Patients - Stock Titan
Praxis Precision Medicines Q2 2025 & Study Result Earnings Call Transcript - MarketBeat
What is the dividend policy of Praxis Precision Medicines Inc. stockBuild wealth steadily with proven stock picks - Jammu Links News
What drives Praxis Precision Medicines Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
Published on: 2025-08-03 18:33:45 - Jammu Links News
What is the risk reward ratio of investing in Praxis Precision Medicines Inc. stockInvest confidently with professional market insights - Jammu Links News
What is Praxis Precision Medicines Inc. company’s growth strategyInvest smarter with actionable stock recommendations - Jammu Links News
What makes Praxis Precision Medicines Inc. stock price move sharplyInvest confidently with professional market insights - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):